/
Oncology
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma
16
Pipeline Programs↗
15
Active Trials↗
18
Companies Involved↗
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma is an emerging landscape with 16 programs across 18 companies. The most active players are Beijing InnoCare Pharma Tech Co., Ltd., Dizal Pharmaceuticals. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 28
Phase 37
Approved
No programs
Analysis
Modality Breakdown
87%
Small molecule
13 of 15 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 94% of 16 pipeline programs.
Analysis
Trial Status
36
clinical trials
Completed15 · 42%
Recruiting11 · 31%
Terminated4 · 11%
Active, not recruiting3 · 8%
Withdrawn2 · 6%
Not yet recruiting1 · 3%
Clinical Trials
Trial Activity
36 trials
A Phase 2 Trial of Single-Agent Pirtobrutinib for Elderly Patients With CLL
Recruiting·—·Phase 2·NCT07685717·50 enrolled
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Recruiting·—·Phase 2·NCT06978088·34 enrolled
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting·—·Phase 2·NCT06757647·61 enrolled
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06547944·30 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)